Home  /  Resource Library  /  Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study

Frontline Sequential Immunochemotherapy Plus Lenalidomide for Mantle Cell Lymphoma Incorporating MRD Evaluation: Phase II, Investigator-Initiated, Single-Center Study

ASH 2020: Results of a phase II study investigating lenalidomide combined with chemoimmuontherapy for treatment of high risk mantle cell lymphoma.